Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 0.5q4 | Ranibizumab 0.5 mg every 4 weeks |
| 2q4 | Aflibercept 2 mg every 4 weeks |
| 2q8 | Aflibercept 2 mg every 8 weeks |
| 4DMT | 4D Molecular Therapeutics |
| 8q12 | Aflibercept 8 mg every 12 weeks |
| 8q16 | Aflibercept 8 mg every 16 weeks |
| AAO | American Academy of Ophthalmology |
| AC | Anterior chamber |
| ADL | Activities of daily living |
| AE | Adverse event |
| AESI | Adverse event of special interest |
| AFL | Aflibercept |
| AHFS | American Hospital Formulary Service |
| AMD | Age-related macular degeneration |
| ANCHOR | Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD trial |
| ANCOVA | Analysis of covariance |
| ANG1 | Angiopoietin 1 |
| AREDS | Age-Related Eye Disease Study |
| AREDS2 | Age-Related Eye Disease Study 2 |
| ARMD | Age-related macular degeneration |
| ARMS2 | Age-related maculopathy susceptibility 2 gene |
| ARVO | Association for Research in Vision and Ophthalmology |
| ASRS | American Society of Retina Specialists |
| ATC | Anatomical Therapeutic Chemical classification |
| ATP | Adenosine triphosphate |
| AU$ | Australian dollars |
| BA | Behavior activation |
| BCVA | Best corrected visual acuity |
| BE | Better eye |
| BIA | Budget impact analysis |
| BLQ | Below the limit of quantification |
| BrM | Bruch's membrane |
| BRVO | Branch retinal vein occlusion |
| C3 | Complement component 3 |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CAGR | Compound annual growth rate |
| CATT | Comparison of Age-related Macular Degeneration Treatments Trials |
| CBS | Charles Bonnet syndrome |
| CDA-AMC | Canada's Drug Agency |
| CEA | Cost-effectiveness analysis |
| CER | Cost-effectiveness ratio |
| CFH | Complement factor H |
| CFU | Continuous follow-up |
| CGA | Central geographic atrophy |
| CHF | Swiss francs |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNV | Choroidal neovascularization |
| CNVM | Choroidal neovascular membrane |
| CONAN | Consensus on Neovascular Age-Related Macular Degeneration Nomenclature |
| COVID-19 | Coronavirus disease 2019 |
| CPT | Current Procedural Terminology |
| CRA | Caregiver Reaction Assessment |
| CRC | California Retina Consultants |
| CrI | Credible interval |
| CSFT | Central subfield thickness |
| CST | Central subfield thickness |
| CUR | Cost-utility ratio |
| CYP | Cytochrome P450 |
| DAA | Disease activity assessment |
| DALY | Disability-adjusted life-year |
| DDD | Defined daily dose |
| DME | Diabetic macular edema |
| DMO | Diabetic macular oedema |
| DSF | Dead-space-free syringe |
| DSMC | Data and safety monitoring committee |
| EDNA | Early Detection of Neovascular Age-related macular degeneration study |
| eIND | Exploratory investigational new drug application |
| EMA | European Medicines Agency |
| EQ-5D | EuroQol 5-dimension questionnaire |
| ETDRS | Early Treatment Diabetic Retinopathy Study |
| EURETINA | European Society of Retina Specialists |
| FA | Fluorescein angiography |
| FAF | Fundus autofluorescence |
| FDA | U.S. Food and Drug Administration |
| FDCA | Federal Food, Drug, and Cosmetic Act |
| FFA | Fundus fluorescein angiography |
| FGFR2 | Fibroblast growth factor receptor 2 |
| GA | Geographic atrophy |
| GBD | Global Burden of Disease |
| GDP | Gross domestic product |
| GLM | Generalized linear model |
| GLP | Good Laboratory Practice |
| H2 | Second half of the year |
| HADS | Hospital Anxiety and Depression Scale |
| HCP | Healthcare professional |
| HCPCS | Healthcare Common Procedure Coding System |
| HDq12 | Aflibercept 8 mg (EYLEA HD) every 12 weeks |
| HDq16 | Aflibercept 8 mg (EYLEA HD) every 16 weeks |
| HOME | Home Monitoring of the Eye study |
| HR | Hazard ratio |
| HRM | Hyperreflective material |
| HRQL | Health-related quality of life |
| HTRA1 | High-temperature requirement A serine peptidase 1 gene |
| HUI-3 | Health Utilities Index Mark 3 |
| iADL | Instrumental activities of daily living |
| IAI | Intravitreal aflibercept injection |
| IC50 | Half-maximal inhibitory concentration |
| ICD-10 | International Classification of Diseases, Tenth Revision |
| ICER | Incremental cost-effectiveness ratio |
| ICG | Indocyanine green |
| ILMA | Intralesional macular atrophy |
| IND | Investigational new drug application |
| IOI | Intraocular inflammation |
| IOP | Intraocular pressure |
| IQR | Interquartile range |
| IRF | Intraretinal fluid |
| IRIS | Intelligent Research in Sight registry |
| IVAN | Inhibition of VEGF in Age-related Choroidal Neovascularisation trial |
| IVFA | Intravenous fluorescein angiography |
| IVT | Intravitreal |
| LD | Loading dose |
| LLOQ | Lower limit of quantification |
| logMAR | Logarithm of the minimum angle of resolution |
| LOVIT | Veterans Affairs Low Vision Intervention Trial |
| LS | Least squares |
| LTFU | Lost to follow-up |
| LVR | Low vision rehabilitation |
| M36 | Month 36 |
| MA | Macular atrophy; Medicare Advantage |
| MARINA | Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD |
| MedDRA | Medical Dictionary for Regulatory Activities |
| MedPAC | Medicare Payment Advisory Commission |
| MMP9 | Matrix metalloproteinase 9 gene |
| MNV | Macular neovascularization |
| MPS | Macular Photocoagulation Study |
| mRNA | Messenger ribonucleic acid |
| MSVI | Moderate and severe vision impairment |
| n-AMD | Neovascular age-related macular degeneration |
| N/A | Not applicable or not available |
| NA | Nonadherence; not available |
| nAMD | Neovascular age-related macular degeneration |
| NCT | National Clinical Trial (ClinicalTrials.gov identifier) |
| NDA | New Drug Application |
| NEI VFQ-25 | National Eye Institute 25-item Visual Function Questionnaire |
| NH | Nursing home |
| NHANES | National Health and Nutrition Examination Survey |
| NHP | Non-human primate |
| NHS | National Health Service (United Kingdom) |
| NI | Non-inferiority |
| NICE | National Institute for Health and Care Excellence |
| NMB | Net monetary benefit |
| NOA | Notal OCT Analyzer |
| NOK | Norwegian kroner |
| NPDR | Non-proliferative diabetic retinopathy |
| NV | Neovascularization |
| NV-AMD | Neovascular age-related macular degeneration |
| NVAMD | Neovascular age-related macular degeneration |
| NVHO | Notal Vision Home OCT |
| OCT | Optical coherence tomography |
| OCTA | Optical coherence tomography angiography |
| OD | Right eye (oculus dexter) |
| OR | Odds ratio |
| OS | Left eye (oculus sinister) |
| OTX-TKI | Development code for the axitinib intravitreal implant |
| OU | Both eyes (oculus uterque) |
| OWSA | One-way sensitivity analysis |
| PCV | Polypoidal choroidal vasculopathy |
| PDGF | Platelet-derived growth factor |
| PDGFR | Platelet-derived growth factor receptor |
| PDS | Port delivery system with ranibizumab |
| PDT | Photodynamic therapy |
| PED | Pigment epithelial detachment |
| PEDF | Pigment epithelium-derived factor |
| PEG | Polyethylene glycol |
| PhI/IIa | Phase 1/2a |
| PHP | Preferential hyperacuity perimetry |
| PK | Pharmacokinetic |
| PLA | Polylactic acid |
| PLGA | Poly(lactic-co-glycolic acid) |
| PRN | Pro re nata (as needed) |
| PSC | Posterior subcapsular cataract |
| PVA | Polyvinyl alcohol |
| PVD | Posterior vitreous detachment |
| Q1 | Quartile 1 |
| Q12W | Every 12 weeks |
| Q16W | Every 16 weeks |
| Q2 | Quartile 2 |
| Q24W | Every 24 weeks |
| Q3 | Quartile 3 |
| Q4 | Quartile 4; fourth quarter |
| Q6M | Every 6 months |
| Q8W | Every 8 weeks |
| QALY | Quality-adjusted life-year |
| QCDR | Qualified Clinical Data Registry |
| QoL | Quality of life |
| RAP | Retinal angiomatous proliferation |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| ROI | Return on investment |
| ROS | Reactive oxygen species |
| RPD | Reticular pseudodrusen |
| RPE | Retinal pigment epithelium |
| Rq4 | Ranibizumab every 4 weeks |
| RR | Relative risk |
| RVO | Retinal vein occlusion |
| RWE | Real-world evidence |
| SAE | Serious adverse event |
| SAP | Statistical analysis plan |
| SCID-IV | Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition |
| SCS | Suprachoroidal space |
| SD | Standard deviation |
| SD-OCT | Spectral-domain optical coherence tomography |
| SE | Standard error |
| SEC | U.S. Securities and Exchange Commission |
| SEM | Standard error of the mean |
| SF-6D | Short Form 6-Dimension |
| SFNV | Subfoveal neovascularization |
| SPA | Special Protocol Assessment |
| SRF | Subretinal fluid |
| SS | Swept-source |
| ST | Supportive therapy |
| T&E | Treat-and-extend |
| TAE | Treat-and-extend |
| TAP | Treatment of Age-Related Macular Degeneration with Photodynamic Therapy study |
| TBD | To be determined |
| TD-OCT | Time-domain optical coherence tomography |
| TEAE | Treatment-emergent adverse event |
| TIE2 | Tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 |
| TKI | Tyrosine kinase inhibitor |
| TNF | Tumor necrosis factor |
| TREX | Treat-and-extend |
| TTO | Time trade-off |
| U.S. | United States |
| UGT1A1 | Uridine diphosphate glucuronosyltransferase 1A1 |
| UI | Uncertainty interval |
| UK | United Kingdom |
| US | United States |
| US$ | United States dollars |
| USA | United States of America |
| USD | United States dollars |
| VA | Visual acuity |
| VD | Visual disability |
| VEGF | Vascular endothelial growth factor |
| VEGF-A | Vascular endothelial growth factor A |
| VEGFR | Vascular endothelial growth factor receptor |
| VEGFR1 | Vascular endothelial growth factor receptor 1 |
| VEGFR2 | Vascular endothelial growth factor receptor 2 |
| VEGFR3 | Vascular endothelial growth factor receptor 3 |
| VF | Vial fractionation |
| VF-14 | Visual Function Index 14 |
| VIEW | VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD trials |
| VISION | VEGF Inhibition Study in Ocular Neovascularization |
| VL | Vision loss |
| VRQoL | Vision-related quality of life |
| VTRD | Vision-threatening retinal disease |
| W104 | Week 104 |
| wAMD | Wet age-related macular degeneration |
| WE | Worse eye |
| WHO | World Health Organization |
| WTP | Willingness to pay |